Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
BUSINESS
Shionogi Gets New Oral COVID-19 Drug into Clinic in Less than 1 Year, Now Gearing Up for PII/III
Shionogi is developing an oral drug for COVID-19 at a pace that was unthinkable prior to the coronavirus pandemic. Other companies have repurposed molecules previously developed for other infections such as SARS and MARS, but Shionogi is attempting to develop…
To read the full story
Related Article
- Shionogi Launches 4th-Dose COVID Jab Trial for Ages 60-Plus
July 27, 2022
- Shionogi Begins COVID-19 Vaccine Trial in Children Aged 5-11
July 20, 2022
- Shionogi’s COVID-19 Vaccine Enters PII/III with Japanese Adolescents
May 17, 2022
- Shionogi’s COVID-19 Pill Improves Respiratory and Feverish Symptoms
April 26, 2022
- Large-Scale Japan Trial for Shionogi Jab Confirms No Major Safety Concerns, Increase in Antibody Titers
April 25, 2022
- Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
March 25, 2022
- FDA Clears Shionogi’s COVID-19 Pill for Global PIII Study
March 17, 2022
- Shionogi’s COVID-19 Jab Non-Inferior to Pfizer Shot in Japan Booster Trial
March 7, 2022
- Japan to Expedite Review for Shionogi’s COVID-19 Pill: PM
March 1, 2022
- Shionogi Files COVID-19 Pill in Japan, Seeks Conditional Approval
February 25, 2022
- Lawmakers Mixed on Use of Conditional Approval for Shionogi’s COVID-19 Pill
February 16, 2022
- MHLW to Consider Conditional Approval for Shionogi COVID Pill: Minister
February 9, 2022
- Shionogi Looks to File COVID Pill in Japan as Early as Next Week
February 8, 2022
- Japan Mulls Early Conditional Approval for Shionogi’s COVID Pill
February 8, 2022
- Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
February 1, 2022
- Shionogi’s COVID-19 Vaccine Enters Japan PIII, AstraZeneca Jab as Control
January 18, 2022
- Shionogi’s COVID-19 Pill Submission Delaying into 2022 as Recruitment Hits Snag
January 6, 2022
- Shionogi Launches Global PIII for COVID-19 Vaccine
December 28, 2021
- Shionogi’s COVID-19 Vaccine Safe and Tolerable, Increases Antibody Titers: Japan PI/II
December 8, 2021
- Shionogi Kicks Off COVID-19 Booster Trial in Japan
December 6, 2021
- Shionogi Wants to Pick Global Partner for Oral COVID-19 Drug by Year-End: President
November 2, 2021
- Shionogi Chief Expresses Eagerness for COVID-19 Drug Rollout, PII/III to Wrap Up by Year-End
September 30, 2021
- Shionogi Kicks Off Japan PII/III Trial for Oral COVID-19 Drug
September 29, 2021
- Shionogi to Begin PII/III Study for Oral COVID-19 Drug on Sept. 27: President
September 24, 2021
- Shionogi’s Oral COVID-19 Drug Enters PI in Japan
July 27, 2021
BUSINESS
- Santen Files RVL Pharma’s Droopy Eyelid Drug in Japan
December 27, 2024
- J&J Bags Kaken’s STAT6 Inhibitor, Set to Take 6% Stake in Japan Firm
December 27, 2024
- Meiji Pharma Sues CDP Lawmaker for Defamation over Kostaive
December 26, 2024
- ASKA In-Licenses Another Women’s Health Drug from Insud
December 26, 2024
- Sandoz’s Rituximab Biosimilar Adds Pediatric ITP Indication
December 26, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…